Introduction
============

Following coronary revascularisation, patients are still vulnerable to a low cardiac output state and tissue hypoperfusion. Some patients may require bridging therapy in order to realise the benefits of revascularisation. There is substantial geographic variation, but it is estimated that between 8 and 25% of patients undergoing coronary revascularisation require inotropic support for myocardial dysfunction \[[@B1]-[@B3]\]. This group of patients carry a substantial burden of morbidity and mortality \[[@B4]\]. Pharmacologic support is commonly limited to catecholaminesand phosphodiesterase III inhibitors (PDEIs) with levosimendan gaining prominence \[[@B5]\]. There is a lack of suitably powered randomised control trails to guide the choice of inotrope in this group of patients. Both catecholamines and PDEIs are associated with increased post-operative myocardial oxygen consumption and arrythmogenesis \[[@B6]\]. Additionally catecholamines have also been associated with impaired coronary vasodilatatory reserve \[[@B7]\].

Levosimendan sensitises myofilaments to calcium by binding to the calcium saturated troponin C, increasing their load-independent contraction \[[@B8]\]. The pleiotropic effects of levosimendan include vasodilatation by opening ATP-sensitive potassium channels (K~ATP~) in vascular smooth muscle as well as in mitochondrial K~ATP~channels.

Early clinical trials, though underpowered, have suggested that levosimendan would be useful in the setting of post coronary revascularisation myocardial dysfunction. More recently there have been several completed clinical trials in this group of patients. The principal objective of this study was to evaluate the association between levosimendan, compared with conventional therapy on mortality, in randomised control trialsin patients having coronary revascularisation.

Materials and methods
=====================

Search strategy
---------------

The primary search for randomised clinical trials (RCTs) was conducted using Pubmed, EMBASE and the Cochrane Registry of Clinical Trials. The search term used was \'levosimendan\'. The search was combined with filters to identify RCTs in the Pubmed and EMBASE database and is available as supplementary material (see Additional file [1](#S1){ref-type="supplementary-material"} for details). We also searched the metaRegister of Controlled Trials using the term \'levosimendan\' \[[@B9]\]. No language restriction was placed but the search was limited to adult human subjects. We used backward snowballing by reviewing the bibliographies of included RCTs and review articles to identify otherwise unrecognised publications. The electronic database search included publications from 1966 and was finalised on 31 August 2010. The study did not require ethical approval.

Study selection
---------------

The authors reviewed all abstracts to identify potential RCTs in a standardised manner. The inclusion criteria were reports of RCTs that compared levosimendan to any other therapy for coronary revascularisation in adult humans and reported at least one outcome of interest. Relevant outcomes included mortality, haemodynamic parameters (for example, cardiac index), cardiac enzymes, length of stay and post-procedural atrial fibrillation. If the abstract suggested that the study could potentially meet the inclusion criteria, the full text article was then retrieved and reviewed. Disagreements between reviewers were resolved by consensus.

Data abstraction and study characteristics
------------------------------------------

All included studies were assessed for internal validity and risk of bias according to the Cochrane Collaboration methods. Each report was assessed for the adequacy of allocation concealment, blinding, performance of an intention to treat analysis and the extent of loss to follow-up.

Data included baseline patient characteristics including age and co-morbidity, baseline left ventricular ejection fraction, details of levosimendan dose and specifics of comparator therapy, type of coronary revascularisation, haemodynamic and clinical outcome data. When data was missing attempts were made to contact the authors.

Data synthesis and analysis
---------------------------

Agreement on inclusion of studies was assessed using the kappa statistic. Heterogeneity was measured using the Cochrane Q test and quantified with the *I^2^*statistic. An *I^2^*value of \> 50% was considered at least moderate heterogeneity.

Data from individual studies were collected to allow calculation of odds ratio (OR). The primary analysis was conducted by means of the Peto fixed effects method when I^2^\< 25% and with the random effects model when I^2^\> 25%. Weighted mean difference (WMD) and 95% CI were calculated for continuous variables (haemodynamics and troponin I). The potential for bias was assessed by visual inspection of funnel plots. Sensitivity analyses were conducted by comparing the fixed and random effects models as well as by evaluating the risk of mortality in studies with a low risk of bias only. The analysis was performed using statistical software SPSS 16 (SPSS Chicago, IL, USA) and Revman 5.0 (available from the Cochrane Collaboration Group). The study was performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement \[[@B10],[@B11]\].

Results
=======

There were 680 reports identified by the search, 79 full text articles retrieved for in depth review. We identified 17 eligible studies involving 729 patients that were included in the final analysis. Figure [1](#F1){ref-type="fig"} describes the flow and reasons for exclusion. Agreement on study inclusion was reached in 76 of the 79 cases (kappa = 0.92). The characteristics of the included studies are described in Table [1](#T1){ref-type="table"}. An appraisal of study quality and risk of bias is presented in Table [2](#T2){ref-type="table"}. Overall studies were of variable quality and many reports lacked relevant details to assess selection, performance or reporting bias. A risk of bias graph is included in the supplementary material (see Additional file [2](#S2){ref-type="supplementary-material"} for details).

![**Flow diagram of literature search and selection process of the studies**.](cc10263-1){#F1}

###### 

Description of the studies included in the meta-analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source                                 Year   Patients   Mean Age\          Setting       Time of administration                      Mean Baseline LVEF % ± SD   Control            Follow-up                  
                                                           (years ± SD)                                                                                                                                           
  -------------------------------------- ------ ---------- ------------------ ------------- ------------------------------------------- --------------------------- ------------------ ------------- ------------ ---------------
                                                           **Levosimendan**   **Control**                                                                           **Levosimendan**   **Control**                

                                                                                                                                                                                                                  

  **Al-Shawaf *et al***. \[[@B35]\]      2006   30         60.5 ± 1 1         58 ± 10       Type 2 diabetes with LCOS after CABG.       Post intervention           29 ± 6             31 ± 6        Milrinone    Hospital stay

                                                                                                                                                                                                                  

  **Alvarez *et al***. \[[@B36]\]        2005   30         71.5 ± 5.2         71.9 ± 5.2    Elective CABG with LCOS                     Post intervention           35 ± 5             37 ± 4        Dobutamine   Hospital stay

                                                                                                                                                                                                                  

  **Alvarez *et al***. \[[@B37]\]        2006   50         71.2 ± 7.2         67.0 ± 8.0    Elective CABG with LCOS                     Post intervention           35 ± 4             34 ± 5        Dobutamine   Hospital stay

                                                                                                                                                                                                                  

  **Barisin *et al***. \[[@B38]\]        2004   33         62.4 ± 7.1         57.9 ± 10.4   Elective OPCAB with good LV function        Pre- intervention           62 ± 8             58 ± 10       Placebo      Hospital stay

                                                                                                                                                                                                                  

  **De Hert *et al***. \[[@B39]\]        2007   30         67 ± 11            69 ± 10       Elective CABG                               Intraoperatively            24 ± 6             27 ± 3        Milrinone    Hospital stay

                                                                                                                                                                                                                  

  **De Hert *et al***. \[[@B40]\]        2008   60         67.5 ± 9.5         69 ± 10       Elective CABG                               Inraoperatively             22 ± 5             25 ± 3        Milrinone    Hospital stay

                                                                                                                                                                                                                  

  **De Luca *et al***. \[[@B41]\]        2005   26         58.6 ± 8.7         57.1 ± 9.3    Acute MI undergoing PCI                     Post intervention           28 ± 3             30 ± 3        Placebo      Hospital stay

                                                                                                                                                                                                                  

  **Eriksson *et al***. \[[@B42]\]       2009   60         64 ± 10            64 ± 10       Elective CABG with LVEF\<50%                Intraoperatively            36 ± 8             36 ± 8        Placebo      Hospital stay

                                                                                                                                                                                                                  

  **Fuhrmann *et al***. \[[@B33]\]       2008   32         68 ± 74            68 ± 8.1      Cardiogenic shock after acute MI            Post intervention           22 ± 9             27 ± 10       Enoximone    Hospital stay

                                                                                                                                                                                                                  

  **Husedzinovic *et al***. \[[@B43]\]   2005   24         61 ± 5.4           61 ± 5.3      Elective OPCAB with normal LVEF             Pre- intervention           56 ± 5             59 ± 2        placebo      Hospital stay

                                                                                                                                                                                                                  

  **Jarvela *et al***. \[[@B44]\]        2008   24         69 ± 11            67 ± 10       Elective AVR and CABG                       Intraoperatively            50 ± 4             65 ± 5        Placebo      Hospital stay

                                                                                                                                                                                                                  

  **Levin *et al***. \[[@B45]\]          2008   137        62.4               61.7          LCOS after elective CABG                    Post intervention           37 ± 4             38 ± 5        Dobutamine   Hospital stay

                                                                                                                                                                                                                  

  **Lilleberg *et al***. \[[@B46]\]      1998   23         56.9 ± 7.9         59 ± 5.7      Elective low risk CABG                      Post intervention           61 ± 9             58 ± 9        Placebo      Hospital stay

                                                                                                                                                                                                                  

  **Samimi-Fard *et al***. \[[@B47]\]    2008   22         65 ± 12            63 ± 11       Acute MI with Cardiogenic shock after PCI   Post intervention           29 ± 2             30 ± 3        Dobutamine   Two years

                                                                                                                                                                                                                  

  **Sonntag *et al***. \[[@B48]\]        2004   24         60                 60            PCI after acute MI                          Post intervention           58 ± 3             62 ± 4        Placebo      Hospital stay

                                                                                                                                                                                                                  

  **Tritapepe *et al***. \[[@B49]\]      2006   24         66.5 ± 5.9         69.5 ± 5.6    Elective CABG                               Pre- intervention           50 ± 7             52 ± 5        Placebo      Hospital stay

                                                                                                                                                                                                                  

  **Tritapepe *et al***. \[[@B1]\]       2009   106        66.5 ± 7.8         64\. ± 8      Elective CABG                               Pre- intervention           44 ± 10            42 ± 11       Placebo      Hospital stay
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CABG, coronary artery bypass graft; LCOS, low cardiac output state; LVEF, left ventricular ejection fraction; MI, myocardial infarction; OPCAB, off pump coronary artery bypass graft; PCI, primary coronary intervention.

###### 

Risk of bias assessment of included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source                                 Adequate sequence generation   Allocation concealment     Blinding                                   Incomplete outcome data addressed   Free of selective reporting   Free of other Bias   Concurrent therapies similar   Overall risk of bias
  -------------------------------------- ------------------------------ -------------------------- ------------------------------------------ ----------------------------------- ----------------------------- -------------------- ------------------------------ ----------------------
  **Al-Shawaf *et al***. \[[@B35]\]      Unclear                        Yes (sealed envelopes)     No                                         Unclear                             Yes                           Yes                  Yes                            Moderate

  **Alvarez *et al***. \[[@B36]\]        unclear                        Unclear                    No                                         Unclear                             Yes                           Yes                  Yes                            Moderate

  **Alvarez *et al***. \[[@B37]\]        unclear                        Unclear                    No                                         Unclear                             Yes                           Yes                  Yes                            Moderate

  **Barisin *et al***. \[[@B38]\]        Yes (computer generated)       Yes                        Yes (patients, doctors, adjudicators)      Unclear                             Yes                           Yes                  Yes                            Low

  **De Hert *et al***. \[[@B39]\]        Yes (computer generated)       Yes (sealed envelopes)     Yes (adjudicators)                         Unclear                             Yes                           Yes                  Yes                            Low

  **De Hert *et al***. \[[@B40]\]        Yes (computer generated)       Yes (sealed envelopes)     Yes(adjudicators)                          Unclear                             Yes                           Yes                  Yes                            Low

  **De Luca *et al***. \[[@B41]\]        Unclear                        Unclear                    No                                         Unclear                             Yes                           Yes                  Yes                            Moderate

  **Eriksson *et al***. \[[@B42]\]       Yes (permutated bocks)         Yes                        Yes (patients, doctors)                    Unclear                             Yes                           Yes                  Yes                            Low

  **Fuhrmann *et al***. \[[@B33]\]       Yes (computer generated)       Yes (computer generated)   Yes (patients doctors)                     Unclear                             Yes                           Yes                  Yes                            Low

  **Husedzinovic *et al***. \[[@B43]\]   Yes (casting lots)             Yes                        Yes (patients, adjudicators)               Unclear                             Yes                           Yes                  Yes                            Moderate

  **Jarvela *et al***. \[[@B44]\]        Yes (computer generated)       Yes (sealed envelopes)     Yes (patients, doctors, adjudicators)      Unclear                             Yes                           Yes                  Yes                            Low

  **Levin *et al***. \[[@B45]\]          Yes (computer generated)       Unclear                    No                                         Unclear                             Yes                           Yes                  Yes                            Moderate

  **Lilleberg *et al***. \[[@B46]\]      Unclear                        Unclear                    Yes (patients, doctors, adjudicators)      Unclear                             Yes                           Yes                  Yes                            Moderate

  **Samimi-Fard *et al***. \[[@B47]\]    Unclear                        Unclear                    No                                         Unclear                             Yes                           Yes                  Yes                            Moderate

  **Sonntag *et al***. \[[@B48]\]        Unclear                        Yes                        Yes (patients, doctors, adjudicators)      Unclear                             Yes                           Yes                  Yes                            Moderate

  **Tritapepe *et al***. \[[@B49]\]      Yes\                           Unclear                    Yes (Patients, physicians, adjudicators)   Unclear                             Yes                           Yes                  Yes                            Low
                                         (computer generated)                                                                                                                                                                                                       

  **Tritapepe *et al***. \[[@B1]\]       Yes (computer generate)        Unclear                    Yes (patients, physicians, adjudicators)   Unclear                             Yes                           Yes                  Yes                            Low
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Analysis of the data showed that, compared with a control intervention, levosimendan was associated with a significant mortality reduction, (19/387 in the levosimendan group vs 39/342 in the control arm) OR 0. 41 (95% CI 0.23 to 0.74, *P*for overall effect 0.005, *P*for heterogeneity = 0.33, I^2^= 12% with a total of 729 patients) (Figure [2](#F2){ref-type="fig"}). A subgroup analysis comparing the effect of levosimendan on mortality in elective versus emergency coronary revascularisation was performed. The elective revascularisation showed a statistically significant mortality benefit compared with the emergency revascularisation group (OR 0.36, 95% CI 0.18 to 0.72, *P*for overall effect = 0.003, I^2^= 0% compared with OR 0.61, 95% CI 0.19 to 1.89, *P*for overall effect = 0.39, I^2^= 69% respectively). All the emergency revascularisations were PCI. The overall result was consistent when a random effects model was used (OR 0.43 (95% CI 0.21 to 0.89)).

![**Forest plot for risk of mortality with subgroups elective and emergency revascularisation**.](cc10263-2){#F2}

Levosimendan had a favourable effect on cardiac index (standardised mean difference 1.63, 95% CI 1.43 to 1.83, *P*for overall effect \< 0.00001) although there was significant heterogeneity (*P*\< 0.000001 I^2^= 95%). A sub-group analysis was undertaken to explore the heterogeneity. Subgroups were defined by the comparator drug, that is, the placebo, dobutamine or phosphdiesterase inhibitors. The sub-group analysis did not show any difference in treatment effect (Figure [3](#F3){ref-type="fig"}).

![**Forest plot for cardiac index with sub-groups dobutamine, placebo and phosphodiesterase inhibitors**.](cc10263-3){#F3}

Post revascularisation, troponin I levels were significantly higher in the control group compared with the levosimendan group (mean difference -1.59, 95% CI 1.78 to 1.40, *P*for overall effect \< 0.00001, *P*for heterogeneity \< 0.00001, I^2^= 95%) with 361 patients included (Figure [4](#F4){ref-type="fig"}).

![**Forest plot of comparison of levosimendan vs control with Troponin I level as the outcome measure outcome**.](cc10263-4){#F4}

There was a significantly lower rate of post-revascularisation new-onset atrial fibrillation in the levosimendan treated group (OR 0.54, 95% CI 0.36 to 0.82, *P*for effect = 0.004, *P*for heterogeneity 0.84, I^2^= 0% for 465 patients (Figure [5](#F5){ref-type="fig"}). There was also a significant difference in the length of intensive care stay in favour of levosimendan compared with control (random effects model, mean difference - 26.18 hours 95% CI 46.20 to 6.16, *P*for heterogeneity \< 0.00001, I^2^= 95%, *P*for overall effect *P*= 0.01) (Figure [6](#F6){ref-type="fig"}). The likelihood of small study bias robustness was evaluated by inspection of the funnel plot (Figure [7](#F7){ref-type="fig"}). Inspection of the funnel plot found no major evidence of such bias and added to the validity and robustness of the study. A sensitivity analysis that only included those studies with a low risk of bias (Table [1](#T1){ref-type="table"}) found an OR of 0.25 (95% CI 0.09 to 0.68). A further sensitivity analysis to establish differential effects based on the comparator was performed. The largest effect size was observed in the levosimendan versus phosphodiesterase group (OR 0.23 (95% CI 0.08 to .65)). The levosimendan versus dobutamine group showed a strong trend in favour of levosimendan but was not statistically significant (OR 0.54 95% CI 0.25 to 1.17)). The levosimendan versus placebo group suggested a positive effect in favour of levosimendan but did not achieve statistical significance (OR 0.66 (95% CI 0.11 to 4.08)) (Table [3](#T3){ref-type="table"}).

![**Forest plot comparing rates of post revascularisation atrial fibrillation for levosimendan versus control**.](cc10263-5){#F5}

![**Forest plot comparing length of stay in the levosimendan versus control groups**.](cc10263-6){#F6}

![**Funnel Plot for risk of mortality including all studies**.](cc10263-7){#F7}

###### 

A sensitivity analysis

                                          Number of studies   OR     95% CI         *P*for overall effect   I^2^%
  --------------------------------------- ------------------- ------ -------------- ----------------------- -------
  Studies with low risk of bias           8                   0.25   0.09 to 0.68   0.007                   0
  Levosimendan versus placebo             9                   0.66   0.11 to 4.08   0.65                    35
  Levosimendan versus phosphodiesterase   4                   0.23   0.08 to 0.65   0.003                   0
  Levosimendan versus dobutamine          4                   0.54   0.25 to 1.17   0.12                    43

A sensitivity analysis including only studies with a low risk of bias, and comparing levosimendan to placebo, phosphodiesterase inhibitors and dobutamine.

OR, odds ratio; I^2,^heterogeneity

Discussion
==========

Cardiogenic shock (CS) is a devastating complication of ST-segment myocardial infarction (STEMI) and occurs in 5 to 8% of these patients \[[@B12]\]. Thirty-day survival of STEMI patients in cardiogenic shock is between 40% and 60% \[[@B12],[@B13]\]. Despite favourable trends in the last 30 years, survival to 6 years remains poor and may be as low as 30% \[[@B14]-[@B16]\]. This is comparable to many forms of cancer. Therapeutic options for haemodynamic support after coronary revascularisation are limited to pharmacologic or mechanical interventions. Pharmacologic choices are vasopressors and inotropic drugs. Inotropic agents are essential to address the contractile dysfunction that occurs by providing short-term haemodynamic improvement. However, this happens at a cost of increased oxygen demand, arrythmogenesis and potential myocardial injury at a time when the myocardium is most vulnerable. Data on comparison between inotropes are scant and recent reports have highlighted the challenge in selecting the best pharmacologic option \[[@B17]-[@B19]\]. Compared with norepinephrine, the use of dopamine in patients with cardiogenic shock has been associated with an increased rate of death \[[@B17]\].

A recent meta-analysis evaluated the use of levosimendan in a variety of patient populations that included post-cardiac surgery, post-vascular surgery, sepsis, decompensated heart failure and post percutaneous coronary intervention (PCI) patients \[[@B20]\]. The proposed mechanisms of myocardial dysfunction in sepsis, after non-cardiac surgery and in the context of cardiogenic shock, are all quite disparate \[[@B21],[@B22]\]. This implies that vasoactive drugs may perform differently, depending on the prevailing mechanism of shock making the interpretation of a pooled analysis of such a heterogeneous group of patients difficult. For this reason we limited this meta-analysis to patients having coronary revascularisation.

Overall, this study shows a mortality benefit when levosimendan was used in patients having coronary revascularisation. The effect was significant in the elective revascularisation group. The subset of patients undergoing emergency revascularisation was under-represented and the mortality benefit in this group was not statistically significant. This latter analysis is probably underpowered. Additionally, levosimendan was associated with favourable outcomes in several clinically important endpoints. The rate of post-revascularisation atrial fibrillation was reduced. Atrial fibrillation after coronary revascularisation is associated with a prolonged hospital stay, increased morbidity and long-term mortality \[[@B23]\]. The analysis also found levosimendan to be associated with a reduction in peri-procedural cardiac troponin I levels. Elevations in cardiac troponin I levels are a valuable marker of myocardial damage after coronary revascularisation and have been associated with a significantly higher rate of in-hospital and long-term mortality \[[@B24]-[@B27]\]. The haemodynamic response to levosimendan was also favourable. It is likely that the improvement of haemodynamic profile observed with levosimendan can be sustained for a longer period of time compared to dobutamine or milrinone \[[@B28]\]. This is because levosimendan has a poorly protein-bound active metabolite and may exert clinical effects for up to a week \[[@B29]\], at a much lower energy expenditure than conventional inotropes.

The sub-group analysis comparing levosimendan to the placebo, dobutamine and phoshodiesterase inhibitors all showed a favourable trend towards levosimendan with only the latter group showing statistical significance. This observation could be interpreted as potential harm from exposure to phosphodiesterase inhibitors. Levosimendan reduced the ICU length of stay by a mean of 26.18 hours (95% CI 46.20 to 6.16). The estimated mean cost of critical care is US\$3,518/day in the United States and about £1,647/day in the United Kingdom \[[@B30],[@B31]\]. Levosimendan is considerably more expensive than conventional treatment and this probably warrants further pharmaco-economic evaluation.

The findings of this meta-analysis must be viewed in the context of other randomised studies and systematic reviews comparing other vasoactive agents \[[@B17],[@B29],[@B32]\]. Thackray *et al*. systematically reviewed the use of inotropes in cardiac failure \[[@B32]\]. The drugs included were beta agonists, dobutamine, dopexamine and phosphodiesterase inhibitors. Compared with the placebo, these drugs were found to be associated with a non-significant trend for increased rate of death (OR 1.5, 95% CI 0.51 to 3.92).

Our study has several limitations. Several studies were of sub-optimal quality. Eight of the 17 studies included did not have clear allocation concealment. This has the potential to exaggerate treatment effects. Only five studies explicitly stated that the analysis was done by an intention to treat principle. The study by Fuhrmann had a small number of events(i.e. all cause mortality at 30 days) and was stopped early for patient benefit \[[@B33]\]. This study may potentially represent an exaggerated effect size in favour of levosimendan \[[@B34]\]. The sensitivity analysis considering the effect of levosimendan on mortality across comparator drugs showed a more pronounced effect compared with the phosphodiesterase group. Comparing levosimendan to placebo is probably of little value when suitable alternatives exist. These studies recruited low risk patients with a low event rate. Lower event rates require larger sample sizes and it is unsurprising that no statistically significant mortality difference was demonstrated.

Publication bias may account for some of the effects observed. Selective reporting of smaller studies, usually of lower methodological quality will tend to exaggerate treatment effects. The funnel plot was symmetrical, suggesting a low probability of publication bias. Not all studies reported clinically important outcomes. Only 465 patients were included in the analysis of atrial fibrillation rates and only 470 patients were included in the analysis of length of ICU stay.

Conclusions
===========

This meta-analysis suggests that the use of levosimendan in patients having coronary revascularisation is associated with a significant reduction in mortality. Additionally, the use of levosimendan is also associated with improvement in haemodynamics and reduction in cardiac biomarkers, length of ICU stay and rate of atrial fibrillation. A suitably powered RCT is required to confirm these findings. Additionally, the exact timing and dosing of levosimendan in patients undergoing coronary revascularisation needs to be specifically addressed.

Key messages
============

• Acute cardiovascular dysfunction after coronary revascularisation occurs in about 8% to 25% of patients.

• The short-term use of inotropes is crucial to restoring haemodynamics and tissue perfusion though the ideal inotrope in this group of patents is controversial.

• Levosimendan has a potential role in reducing the mortality and morbidity associated with coronary revascularisation.
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